Skip to main content

Table 3 Relative hazards of infection for tumor necrosis factor inhibitors versus methotrexate

From: The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis

Exposure Comparator Unadjusted relative hazard (95 % CI) Adjusteda relative hazard (95 % CI)
TNFi monotherapy MTX 1.12 (0.70–1.78) 1.19 (0.72–1.94)
TNFi + MTX combination MTX 1.21 (0.69–2.10) 1.23 (0.69–2.17)
 Hospitalized infection during baseline No infection during baseline   3.28 (1.44–7.48)
 Nonprimary hospitalized or outpatient infection during baseline No infection during baseline   1.72 (1.12–2.63)
 High-dose oral GC (≥10 mg/day) No oral GC use during baseline   2.03 (1.21–3.39)
 Low-dose oral GC (<10 mg/day) No oral GC use during baseline   0.86 (0.50–1.46)
  1. TNFi Tumor necrosis factor inhibitor, MTX Methotrexate, GC Glucocorticoid
  2. aMultivariable model included the following variables: new TNFi use, age, sex, asthma, baseline oral GC dose, infection during baseline period
\